Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 14/20 | 0.70 |
| ▸ | AR | P10275 | 3/20 | 0.70 |
| ▸ | IL6 | P05231 | 7/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12272803 | 1.00 | NR3C1 (0.70) | NR3C1ARIL6CFTRALDH1A1 | |
| SCHEMBL12494047 | 1.00 | NR3C1 (0.70) | NR3C1ARIL6CFTRALDH1A1 | |
| SCHEMBL12272220 | 1.00 | NR3C1 (0.70) | NR3C1ARIL6CFTRALDH1A1 | |
| SCHEMBL12271823 | 0.94 | NR3C1 (0.62) | NR3C1ARIL6CFTRMEN1 | |
| SCHEMBL12272688 | 0.94 | NR3C1 (0.62) | NR3C1ARIL6CFTRMEN1 | |
| SCHEMBL12271720 | 0.94 | NR3C1 (0.62) | NR3C1ARIL6CFTRMEN1 | |
| SCHEMBL12272337 | 0.94 | NR3C1 (0.62) | NR3C1ARIL6CFTRMEN1 | |
| SCHEMBL13494367 | 0.89 | NR3C1 (0.77) | NR3C1ARIL6CFTRALDH1A1 | |
| SCHEMBL1571729 | 0.89 | NR3C1 (0.77) | NR3C1ARIL6CFTRALDH1A1 | |
| SCHEMBL12271690 | 0.89 | NR3C1 (0.77) | NR3C1ARIL6CFTRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901310-B2 | Tricyclic compounds, compositions, and methods | PFIZER INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140316139-A1 | Tricyclic Compounds, Compositions, And Methods | PFIZER INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140316139-A1 | Tricyclic Compounds, Compositions, And Methods | PFIZER INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140142316-A1 | Tricyclic Compounds, Compositions, And Methods | PFIZER INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142316-A1 | Tricyclic Compounds, Compositions, And Methods | PFIZER INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2685821-A1 | NUCLEAR HORMONE RECEPTOR MODULATORS | AbbVie Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8445520-B2 | Tricyclic compounds, compositions, and methods | PFIZER INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445520-B2 | Tricyclic compounds, compositions, and methods | PFIZER INC. (US) | 2013-05-21 | — | — | US | disclosed |
| WO-2012125797-A1 | NUCLEAR HORMONE RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012125797-A1 | NUCLEAR HORMONE RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2012-09-20 | — | — | WO | disclosed |
| US-7598231-B2 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4b,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; modulators of the glucocorticoid receptor; asthma, dermatitis, inflammatory bowel disease, Alzheimer's disease, psychotic major depression | PFIZER, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598231-B2 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4b,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; modulators of the glucocorticoid receptor; asthma, dermatitis, inflammatory bowel disease, Alzheimer's disease, psychotic major depression | PFIZER, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7547714-B2 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4 beta ,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; glucocorticoid receptor modulators; antiinflammatory agents; Alzheimer's disease | PFIZER, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547714-B2 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4 beta ,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; glucocorticoid receptor modulators; antiinflammatory agents; Alzheimer's disease | PFIZER, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080312294-A1 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4 beta ,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; glucocorticoid receptor modulators; antiinflammatory agents; Alzheimer's disease; side effect reduction | PFIZER, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312294-A1 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4 beta ,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; glucocorticoid receptor modulators; antiinflammatory agents; Alzheimer's disease; side effect reduction | PFIZER, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| WO-2008093227-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS GLUCOCORTICOID RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20080188443-A1 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4b,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; modulators of the glucocorticoid receptor; asthma, dermatitis, inflammatory bowel disease, Alzheimer's disease, psychotic major depression | PFIZER, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188443-A1 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4b,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; modulators of the glucocorticoid receptor; asthma, dermatitis, inflammatory bowel disease, Alzheimer's disease, psychotic major depression | PFIZER, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2008093236-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS GLUCOCORTICOID RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188443-A1 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4b,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; modulators of the glucocorticoid receptor; asthma, dermatitis, inflammatory bowel disease, Alzheimer's disease, psychotic major depression | NR3C1, NR3C2, MC2R | NR3C1 1/4885AR 833/4885IL6 694/4885 |
| US-20140142316-A1 | Tricyclic Compounds, Compositions, And Methods | NR3C2, NR3C1, MC2R | NR3C1 2/4885AR 73/4885IL6 2312/4885 |
| US-20140316139-A1 | Tricyclic Compounds, Compositions, And Methods | NR3C2, NR3C1, MC2R | NR3C1 2/4885AR 73/4885IL6 2312/4885 |
| US-20080312294-A1 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4 beta ,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; glucocorticoid receptor modulators; antiinflammatory agents; Alzheimer's disease; side effect reduction | NR3C1, NR3C2, MC2R | NR3C1 1/4885AR 179/4885IL6 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.